QQQ   415.91 (-1.77%)
AAPL   164.21 (-1.69%)
MSFT   398.88 (-1.33%)
META   483.13 (-3.72%)
GOOGL   153.17 (-1.82%)
AMZN   174.75 (-2.49%)
TSLA   148.59 (-0.89%)
NVDA   808.23 (-4.54%)
AMD   148.30 (-4.37%)
NIO   3.81 (-4.75%)
BABA   68.50 (-0.55%)
T   16.32 (-0.06%)
F   12.10 (+0.33%)
MU   106.98 (-4.42%)
GE   148.32 (-3.02%)
CGC   7.94 (+1.40%)
DIS   111.40 (-0.92%)
AMC   3.22 (+10.27%)
PFE   25.80 (+1.61%)
PYPL   61.81 (-0.47%)
XOM   119.97 (+1.22%)
QQQ   415.91 (-1.77%)
AAPL   164.21 (-1.69%)
MSFT   398.88 (-1.33%)
META   483.13 (-3.72%)
GOOGL   153.17 (-1.82%)
AMZN   174.75 (-2.49%)
TSLA   148.59 (-0.89%)
NVDA   808.23 (-4.54%)
AMD   148.30 (-4.37%)
NIO   3.81 (-4.75%)
BABA   68.50 (-0.55%)
T   16.32 (-0.06%)
F   12.10 (+0.33%)
MU   106.98 (-4.42%)
GE   148.32 (-3.02%)
CGC   7.94 (+1.40%)
DIS   111.40 (-0.92%)
AMC   3.22 (+10.27%)
PFE   25.80 (+1.61%)
PYPL   61.81 (-0.47%)
XOM   119.97 (+1.22%)
QQQ   415.91 (-1.77%)
AAPL   164.21 (-1.69%)
MSFT   398.88 (-1.33%)
META   483.13 (-3.72%)
GOOGL   153.17 (-1.82%)
AMZN   174.75 (-2.49%)
TSLA   148.59 (-0.89%)
NVDA   808.23 (-4.54%)
AMD   148.30 (-4.37%)
NIO   3.81 (-4.75%)
BABA   68.50 (-0.55%)
T   16.32 (-0.06%)
F   12.10 (+0.33%)
MU   106.98 (-4.42%)
GE   148.32 (-3.02%)
CGC   7.94 (+1.40%)
DIS   111.40 (-0.92%)
AMC   3.22 (+10.27%)
PFE   25.80 (+1.61%)
PYPL   61.81 (-0.47%)
XOM   119.97 (+1.22%)
QQQ   415.91 (-1.77%)
AAPL   164.21 (-1.69%)
MSFT   398.88 (-1.33%)
META   483.13 (-3.72%)
GOOGL   153.17 (-1.82%)
AMZN   174.75 (-2.49%)
TSLA   148.59 (-0.89%)
NVDA   808.23 (-4.54%)
AMD   148.30 (-4.37%)
NIO   3.81 (-4.75%)
BABA   68.50 (-0.55%)
T   16.32 (-0.06%)
F   12.10 (+0.33%)
MU   106.98 (-4.42%)
GE   148.32 (-3.02%)
CGC   7.94 (+1.40%)
DIS   111.40 (-0.92%)
AMC   3.22 (+10.27%)
PFE   25.80 (+1.61%)
PYPL   61.81 (-0.47%)
XOM   119.97 (+1.22%)
NASDAQ:SBPH

Spring Bank Pharmaceuticals (SBPH) Stock Price, News & Analysis

Notice: This company has been marked as potentially delisted and may not be actively trading.
Today's Range
N/A
50-Day Range
$1.21
$10.39
52-Week Range
N/A
Volume
N/A
Average Volume
177,606 shs
Market Capitalization
$122.94 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
SBPH stock logo

About Spring Bank Pharmaceuticals Stock (NASDAQ:SBPH)

Spring Bank Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapeutics for the treatment of a range of cancers and inflammatory diseases using its proprietary small molecule nucleotide platform. The company is developing SB 11285, a next-generation immunotherapeutic cyclic dinucleotide for the treatment of selected cancers; novel STING antagonist compounds for the treatment of autoimmune and inflammatory diseases; and novel platform to enable the targeted delivery of payload molecules. It has a collaboration agreement with with Roche to explore the co-administration of SB 11285. The company was formerly known as Spring Bank Technologies, Inc. and changed its name to Spring Bank Pharmaceuticals, Inc. in May 2008. Spring Bank Pharmaceuticals, Inc. was founded in 2002 and is headquartered in Hopkinton, Massachusetts.

SBPH Stock News Headlines

When will interest rates go down?
2024's Must-Have Guide: Master Crypto Investment Today
The cryptocurrency revolution is here with Bitcoin soaring past the $70,000 milestone—a clear indicator of the booming digital currency market. Are you prepared to navigate these exciting yet complex waters? Introducing "Navigating the Future: A Comprehensive Guide to Cryptocurrency Investments in 2024." This free digital guide is your essential resource for understanding and capitalizing on cryptocurrency investments, tailored for both newcomers and seasoned investors. (**By clicking the link you are subscribing to The Conservative Investor Newsletter and may receive up to 2 additional free bonus subscriptions. Unsubscribing is easy.)
Man stabbed during street fight in Spring Bank West
2024's Must-Have Guide: Master Crypto Investment Today
The cryptocurrency revolution is here with Bitcoin soaring past the $70,000 milestone—a clear indicator of the booming digital currency market. Are you prepared to navigate these exciting yet complex waters? Introducing "Navigating the Future: A Comprehensive Guide to Cryptocurrency Investments in 2024." This free digital guide is your essential resource for understanding and capitalizing on cryptocurrency investments, tailored for both newcomers and seasoned investors. (**By clicking the link you are subscribing to The Conservative Investor Newsletter and may receive up to 2 additional free bonus subscriptions. Unsubscribing is easy.)
Spring Returns
St. Scholastica to open spring practice
Spring Bank Pharmaceuticals
Spring Bank Pharmaceuticals(SBPH)
See More Headlines
Receive SBPH Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Spring Bank Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
11/08/2020
Today
4/19/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical Preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:SBPH
Fax
N/A
Employees
30
Year Founded
N/A

Profitability

Net Income
$-24,100,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$2.16 per share

Miscellaneous

Free Float
N/A
Market Cap
$122.94 million
Optionable
Not Optionable
Beta
1.07
The 10 Best AI Stocks to Own in 2024 Cover

Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.

Get This Free Report

Key Executives

  • Mr. Martin J. Driscoll (Age 61)
    Pres, CEO & Director
    Comp: $568.08k
  • Dr. Radhakrishna P. Iyer Ph.D. (Age 70)
    FRSC, Co-Founder & Chief Scientific Officer
    Comp: $452.04k
  • Ms. Lori C. Firmani (Age 47)
    VP of Fin., Treasurer, Principal Financial Officer & Principal Accounting Officer
  • Mr. Donald Mitchell MBA
    VP of Operations & Corp. Devel.
  • Mr. Garrett Winslow (Age 41)
    VP of Legal, Sec. & Gen. Counsel
  • Dr. Nezam H. Afdhal (Age 63)
    Chief Medical Officer
  • Dr. Atif Abbas
    VP and Head of Oncology & Immunology Clinical Devel.

SBPH Stock Analysis - Frequently Asked Questions

How were Spring Bank Pharmaceuticals' earnings last quarter?

Spring Bank Pharmaceuticals, Inc. (NASDAQ:SBPH) released its quarterly earnings results on Sunday, November, 8th. The company reported ($0.31) EPS for the quarter, missing analysts' consensus estimates of ($0.25) by $0.06.

What other stocks do shareholders of Spring Bank Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Spring Bank Pharmaceuticals investors own include Intelsat (I), AMC Entertainment (AMC), Bank of America (BAC), Fossil Group (FOSL), Associated British Foods (ABF), Apollo Global Management (APO), Chaarat Gold (CGH), SCYNEXIS (SCYX), Avadel Pharmaceuticals (AVDL) and China Unicom (Hong Kong) (CHU).

When did Spring Bank Pharmaceuticals IPO?

Spring Bank Pharmaceuticals (SBPH) raised $14 million in an initial public offering on Friday, May 6th 2016. The company issued 1,100,000 shares at a price of $12.00-$14.00 per share. Dawson James Securities served as the underwriter for the IPO.

This page (NASDAQ:SBPH) was last updated on 4/19/2024 by MarketBeat.com Staff

From Our Partners